Bear lab (Bear 3rd from left, McCamphill on right)

Scientists Find a New Way to Reverse Symptoms of Fragile X

May 20, 2020

FRAXA Investigator and MIT Professor Mark Bear and his colleagues have identified a valuable new target for Fragile X therapeutics: GSK3 alpha. Several FRAXA research teams previously identified GSK3 beta as a treatment target for Fragile X. The catch is that, so far, GSK3 beta inhibitors have proven too toxic for regular use. Dr. Bear’s new discovery opens up the possibility of developing more selective compounds with less toxicity and fewer side effects. Interestingly, lithium inhibits both GSK3 versions – alpha and beta.

Read More »

Mechanisms of Tolerance to Chronic mGluR5 Inhibition

September 19, 2017

FRAXA supported research showing mGluR5 antagonist tolerance develops quickly in Fragile X models, guiding new strategies to prevent or overcome it.

Read More »

Categories

FRAXA Funded Research

Current Research Grants (37)